Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
KRAS
Biotech
BridgeBio's cancer spinout backs SPAC as path to Nasdaq
The biotech—which spun out of BridgeBio Pharma in May 2024—has $100 million cash to hand, while Helix is bringing $196 million to the table.
James Waldron
Feb 28, 2025 9:25am
High dose of Cardiff's KRAS drug shows 64% ORR, sending stock up
Dec 10, 2024 4:05pm
Roche culls cough candidate, pivots KRAS program in Q3 update
Oct 23, 2024 6:35am
Allist pays Jacobio $21M, landing role in Chinese KRAS race
Aug 30, 2024 9:12am
Genentech sinks SHP2 pact, leaving Relay to race thinning field
Jul 17, 2024 8:01am
Erasca lays off 18%, swaps out KRAS program for fresh options
May 17, 2024 5:30am
